De-Nol in the treatment of reflux esophagitis.
Twenty-eight patients with histologically proven reflux esophagitis were randomly allocated to receive either De-Nol (tripotassium dicitrate bismuthate) or placebo for three weeks. Significant decreases in symptoms frequency and severity were noted in De-Nol group comparing with placebo group (p less than 0.01). Objective improvement in esophageal endoscopic appearance was obtained in 78.5% of the patients treated with De-Nol and only in 14.2% of those receiving placebo. De-Nol appears to be an effective drug in the treatment of reflux esophagitis, but this should be confirmed by further studies.
Balan
G
G
Săndulescu
E
E
Cijevschi
C
C
Stanciu
R
R
Darwish
R
R
Stanciu
C
C
D000328:Adult; D000368:Aged; D001729:Bismuth / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011897:Random Allocation
D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth